Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Both semaglutide and tirzepatide should help people with Type 2 diabetes lower their HbA1c, a measure of blood glucose over ...

Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...

Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15 ...